期刊文献+

非清髓性异基因造血干细胞移植治疗高龄白血病

Non-myeloablative allogeneic hematopoietic stem cells transplantation for the treatment of elderly patients with acute leukemia
下载PDF
导出
摘要 背景:非清髓异基因造血干细胞移植减轻了预处理强度,减少了移植相关的死亡。目的:分析非清髓性异基因造血干细胞移植治疗老年急性白血病的疗效及其安全性。方法:71岁急性单核细胞白血病M5b患者1例,行非清髓性异基因造血干细胞移植。供者为患者同胞弟弟,60岁,HLA5个位点相合,ABO血型相同。预处理用药包括采用氟达拉滨、塞替派、环磷酰胺和马利兰针剂。移植物抗宿主病预防用抗胸腺球蛋白、巴利昔单抗、环孢素A、麦考酚酯肠溶片及丙种球蛋白,移植后并发症防治和支持治疗:更昔洛韦防治巨细胞病毒感染、前列腺素E1、丹参、肝素及熊去氧胆酸防治肝静脉闭塞症,预处理后外周血中性粒细胞低于0.5×109L-1时开始予粒细胞集落刺激因子5μg/(kg?d)促进造血重建。必要时输注辐照的浓缩红细胞和血小板,供者采用粒细胞集落刺激因子,连用7d,第6,7天采集外周血造血干细胞,当天输注给患者。结果与结论:移植后28d完成造血重建。移植后50d,行STR检测结果显示供受者100%一致。移植后+20~30d陆续出现"出血性膀胱炎"、"败血症(洋葱伯克霍尔德菌胞菌)",移植后2个月出现黄疸、肝功能损害,诊断"急性移植物抗宿主病Ⅲ度(肝脏,3级)",经过抗感染、保肝、调整免疫抑制药物治疗后病情缓解。结果表明采用以氟达拉滨为基础的非清髓性外周血造血干细胞移植治疗有多种合并症老年急性白血病是一种有效安全的方法。 BACKGROUND:Non-myeloablative allogeneic hematopoietic stem cells transplantation can reduce the intensity of conditioning regimen,and decrease the transplantation related mortality rate.OBJECTIVE:To analyze the efficacy and safety of non-myeloablative allogeneic hematopoietic stem cells transplantation for the treatment of elderly patients with acute leukemia.METHODS:A 71-year-old female patient with acute mononuclear cell leukemia M5b underwent the non-myeloablative allogeneic hematopoietic stem cells transplantation.The donor was the younger brother of the patient who was 60 years old,ABO blood type was the same and the HLA loci were mismatched.The conditioning regimen contained fludarabine,thiotepa,cyclophosphamide and Myleran,human anti-thymocyte globulin(ATG),basiliximab,cyclosporine,mycophenolate mofetil and gamma globulin were used for graft-versus-host disease(GVHD) prophylaxis.The prophylaxis and support therapy of complication after transplantation consisted of Ganciclovir for cytomegalovirus infection,prostaglandin E1,salvia Miltiorrhiza;Heparin and ursodeoxycholic acid for veno-occlusive disease;Granulocyte colony-stimulating factor(G-CSF) 5 μg/kg per day was used when the absolute neutrophil count decreased to 0.5×10^9 /L.Red cells and platelet were infused if necessary.Peripheral blood stem cells(PBSC) of the donor were mobilized with G-CSF for 7 successive days.PBSC were collected and infused to the patient at the 6th and 7th days.RESULTS AND CONCLUSION:Hemopoiesis and immunology reconstruction was completed at the 28th day after transplantation.Results of short tandem repeat(STR) detection shows that the DNA from the donor was the same as the patient at the 50th day after transplantation.The patient suffered from hemorrhagic cystitis and sepsis(Burkholderiacepacia) after transplantation for 20-30 days.Two months later,the patient presented with jaundice and hepatic impairment and she was diagnosed as having acute GVHD(liver,grade 3).These were controlled with antibiotics and adjusting the regime of immunosuppressive drugs.These findings indicate that non-myeloablative allogeneic hematopoietic stem cells transplantation based on a pretreatment regime containing fludarabine is safe and effective for elderly acute leukemia patients with a variety of complications.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2011年第49期9307-9310,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献20

  • 1John B,Richard C.Non-myeloablative stem cell transplants.British Journal of Haematology.2000;111(1):6-17.
  • 2Hermann S,Klein SA,Jacobi V,et al.Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens.British Journal of Haematology.2001;113(2):446-454.
  • 3王丹红,艾辉胜,郭梅,余长林,乔建辉,孙万军,孙琪云,张石.非清髓异基因外周造血干细胞移植治疗高龄血液病临床研究[J].解放军医学杂志,2003,28(12):1112-1113. 被引量:4
  • 4李庆山,毛平,王顺清,莫文键,张玉平,许世林.高龄供者非清髓性异基因造血干细胞移植后低剂量环孢素A治疗老年急性白血病1例[J].中国组织工程研究与临床康复,2007,11(20):4041-4043. 被引量:5
  • 5Hashmi S,Becker M.Is consolidation chemotherapy necessary before non-myeloablative transplantation in AML?.Leuk Res.2011;35(7):841-843.
  • 6Pollack SM,O'Connor TP,Hashash J,et al.Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation:A Clinical Review.American Journal of Clinical Oncology.2009;32(6):618-628.
  • 7Alyea EP,Kim HT,Ho V,et al.Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than50years of age.Blood.2005;105(4):1810-1814.
  • 8Michele F,Alessandro B,Ileana B,et al.Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies:Results from the GITMO(Gruppo Italiano Trapianto Midollo Osseo)multicenter prospective clinical trial.American Journal of Hematology.2007;82(10):863-866.
  • 9Ying L,Gary VZ,and Stephen J,et al.Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells.Blood.2005;106(4):1479-1487.
  • 10Panagiotis T,Reuven O,Menachem B,et al.A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patient.Haematologica.2006;91(6):852-855.

二级参考文献47

  • 1李庆山,毛平,王顺清,朱志刚,应逸,莫文健,张玉平.非清髓性造血干细胞移植后移植物抗宿主病的临床观察[J].中华器官移植杂志,2006,27(5):297-300. 被引量:8
  • 2李庆山,毛平,王顺清,朱志刚,莫文健,张玉平.非清髓性造血干细胞移植在血液病治疗中应用抗胸腺细胞球蛋白或抗淋巴细胞球蛋白安全性观察[J].临床荟萃,2006,21(21):1563-1565. 被引量:8
  • 3McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects [J]. Blood, 2001, 97(11): 3390-3400.
  • 4Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic lcukaemia[J]. Br J Haematol, 1995, 91(2) : 341.
  • 5Locattelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease[J].Blood, 2003, 101(6): 2137-2143.
  • 6Bruno B, Sorasio R, Patriarca F, et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma[ J]. Eur JHaematol, 2007, 78(4) : 330 - 337.
  • 7Grigg A, Bardy P, Byron K, et al. Fludarabine-base non-myeloblative chemotherapy follow-ed by infusion of HLA-identical stem cells for relapsed[J]. Leuk Lymphoma, 1999, 23(2) : 107 - 112.
  • 8Srinivasan R, Takahashi Y, Mccoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-basedhaematopoietic cell transplantation[J]. Br J Haematol, 2006, 133(3) : 305 -314.
  • 9Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine[ J]. Ann Intern Med, 1998, 129(7) : 559 -566.
  • 10Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-ceIIand plasma cell apoptosis by multiple pathways [J]. Transplantation, 2005, 79(11): 1507- 1515.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部